Completed Suicides in 47 Psychiatric Hospitals in Germany – Results from the AGATE-Study

Abstract

Introduction:

There is an ongoing debate about a possibly enhanced risk of suicidal behaviour in some psychiatric patients due to psychopharmacotherapy. Our retrospective study aimed at analyzing the psychopharmacotherapy of 133 inpatient suicides and 133 controls by a matched pair design.

Methods:

We analyzed all suicides (n=133) reported in the AGATE study from 1991 to 2008. Besides evaluation of sociodemographic variables and suicide methods, we compared psychopharmacotherapy of suicides with schizophrenia (n=59) and affective disorders (n=59) to that of a matched control group.

Results:

Most suicides (n=102, 76.7%) were judged not to be related to psychopharmacotherapy. In general, more psychopharmacological drugs were prescribed for suicides than for controls. Schizophrenic suicides received more low potency FGAs than their controls. More suicides with affective disorders than controls were treated with NASSAs, SNRIs, and high or low potency FGAs. In contrast to their controls, none of the suicides with affective disorders received lithium. NASSAs, SNRIs, and high or low potency FGAs predicted suicide in regression analysis for inpatients with affective disorders.

Discussion:

Differences in psychopharmacotherapy might mainly result from a recognized risk of suicide or a more severe degree of illness. However, the underrepresentation of lithium in the suicide groups is noticeable.

Key words

suicide - psychopharmacotherapy - psychiatric inpatients - AGATE study

• References

• 1 Bowers L, Banda T, Nijman H. Suicide inside. A systematic review of inpatient suicides. J Nerv Ment Dis 2010; 198: 315-328
• 2 Cassells C, Paterson B, Dowding D et al. Long- and short-term risk factors in the prediction of inpatient suicides: review of literature. Crisis 2005; 26: 53-63
• 3 Deisenhammer EA, DeCol C, Honeder M et al. Inpatient suicide in psychiatric hospitals. Acta Psychiatr Scand 2000; 102: 290-294
• 4 Dong JYS, Ho TP, Kan CK. A case-control study of 92 cases of in-patient suicides. J Affect Disord 2005; 87: 91-99
• 5 Neuner T, Schmid R, Wolfersdorf M et al. Predicting inpatient suicides and suicide attempts by clinical routine data?. Gen Hosp Psychiat 2008; 30: 324-330
• 6 Sharma V, Persad E, Kueneman K. A closer look at inpatient suicide. J Affect Disord 1998; 47: 123-129
• 7 Spießl H, Hübner-Liebermann B, Cording C. Suicidal behaviour of psychiatric inpatients. Acta Psychiatr Scand 2002; 106: 134-138
• 8 Steblaj A, Tavcar R, Dernovsek MZ. Predictors of suicide in psychiatric hospital. Acta Psychiatr Scand 1999; 100: 383-388
• 9 FDA. Public Health Advisory. Worsening depression and suicidality in patients being treated with antidepressants March 22 2004; Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvi-sories/ucm161696.htm
• 10 Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332-339
• 11 Whittington CJ, Kendall T, Fonagy P et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341-1345
• 12 FDA. Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications Juni 30 2005; Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053169.htm
• 13 FDA Public Health Advisory . Antidepressant use in children, adolescents, and adults May 2, 2007; Available at http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096273.htm
• 14 Fergusson D, Doucette S, Glass KC et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330: 396
• 15 Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo-controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005; 330: 385
• 16 Reeves RR, Ladner E. Antidepressant-induced suicidality: an update. CNS Neuroscience and Therapeutics 2010; 16: 227-234
• 17 Möller HJ. Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. World J Biol Psychiatry 2009; 10: 180-195
• 18 Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 1993; 8: 186-212
• 19 Rihmer Z. Suicide risk in mood disorders. Curr Opin Psychiatry 2007; 20: 17-22
• 20 Akiskal HS, Benazzi F, Perugi G et al. Agitated “unipolar” depression reconceptualized as depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Dis 2005; 85: 245-258
• 21 Mihanović M, Restek-Petrović B, Bodor D et al. Suicidality and side effects of antidepressants and antipsychotics. Psychiatria Danubia 2010; 22: 79-84
• 22 Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001; 15: 127-135
• 23 Wolfersdorf M. Suicide among psychiatric inpatients. In Hawton K, van Heeringen K. eds. The international handbook of suicide and attempted suicide. Chichester: John Wiley & Sons Ltd; 2000: 457-466
• 24 Haen E. Qualitätssicherung in der Psychopharmakotherapie. Neurotransmitter 2004; 7/8: 37-43
• 25 Gaertner I, Gilot C, Heidrich P et al. A case control study on psychopharmacotherapy before suicide committed by 61 psychiatric inpatients. Pharmacopsychiatry 2002; 35: 37-43
• 26 Proulx F, Lesage AD, Grunberg F. One hundred inpatient suicides. Br J Psychiatry 1997; 171: 247-250
• 27 Taiminen TJ. Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients. Acta Psychiatr Scand 1993; 87: 45-47
• 28 De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 2010; 117: 68-74
• 29 Haukka J, Tiihonen J, Härkänen T et al. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf 2008; 17: 686-696
• 30 Tiihonen J, Wahlbeck K, Lönnqvist J et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333: 224
• 31 Tiihonen J, Lönnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11study). Lancet 2009; 374: 620-627
• 32 Hawton K, Sutton L, Haw C et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005; 187: 9-20
• 33 Hawton K, van Heeringen K. Suicide. Lancet 2009; 373: 1372-1381
• 34 Pompili M, Lester D, Grispini A et al. Completed suicide in schizophrenia: evidence from a case-control study. Psychiatry Res 2009; 167: 251-257
• 35 Aguilar EJ, Siris SG. Do antipsychotic drugs influence suicidal behavior in schizophrenia?. Psychopharmacol Bull 2007; 40: 128-142
• 36 Altamura AC, Bassetti R, Bignotti S et al. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res 2003; 60: 47-55
• 37 Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol 2007; 22: 49-267
• 38 Montout C, Casadebaig F, Lagnaoui R et al. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr Res 2002; 57: 147-156
• 39 Drake RE, Gates C, Cotton PG et al. Suicide among schizophrenics. Who is at risk? J Nerv Ment Dis 1984; 172: 613-617
• 40 Pompili M, Ruberto A, Kotzalidis GA et al. Awareness of illness and suicide in schizophrenia: an overview. Bull Menninger Clin 2004; 68: 297-318
• 41 Shrivastava A, Johnston ME, Shah N et al. Persistent suicide risk in clinically improbe schizophrenia patients: challenge of the suicidal dimension. Neuropsychiatr Dis Treat 2010; 6: 633-638
• 42 Palmer DD, Henter ID, Wyatt RJ. Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia?. J Clin Psychiatry 1999; 60 (S2) 100-103 111–116
• 43 Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91
• 44 Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 2003; 64: S44-S52
• 45 Cipriani A, Pretty H, Hawton K et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819
• 46 Lauterbach E, Felber W, Müller-Oerlinghausen B et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand 2008; 118: 469-479
• 47 Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology 2010; 62: 43-49
• 48 Rubino A, Roskell N, Tennis P et al. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2006; 334: 242
• 49 Mines D, Hill D, Yu H et al. Prevalance of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 2005; 14: 367-372
• 50 Salem BA, Karam EG. Duloxetine and suicide attempts: a possible relation. Clin Pract Epidemiol Ment Health 2008; 4: 18
• 51 Acharya N, Rosen AS, Polzer JP et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006; 26: 587-594
• 52 Courtet P. Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran. Neuropsychiatr Dis Treat 2010; 6: 3-8
• 53 Dubicka B, Hadley S, Roberts C. Suicidal behaviour in youths with depression treated with new-generation antidepressants. Br J Psychiatry 2005; 189: 393-398
• 54 Kasper S, Montgomery SA, Möller HJ et al. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. World J Biol Psychiatry 2010; 11: 36-44
• 55 Stone M, Laughren T, Jones ML et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009; 339: b2880
• 56 Wittmann M, Hausner H, Hajak G et al. Suizidalität und Psychopharmakotherapie im höheren Lebensalter – eine Auswertung der AGATE. Suicidality and psychopharmacological therapy in old age – results from the AGATE. Suizidprophylaxe 2009; 36: 82-88